Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CanVirex04
- Development stage
- Preclinical
- Lead developer
- CanVirex
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
CanVirex04 is an investigational oncolytic virus therapy being developed by CanVirex, a biotechnology company focused on measles virus-based cancer immunotherapies. The candidate utilizes a measles virus (MV) vector platform, specifically derived from the live-attenuated Schwartz vaccine strain, which is engineered to selectively infect and lyse tumor cells (oncolysis) while simultaneously stimulating a systemic anti-tumor immune response. The platform leverages the natural tropism of the measles virus for receptors often overexpressed on cancer cells, such as CD46 and Nectin-4. CanVirex04 is part of a broader portfolio of MV vectors that may be modified with specific therapeutic payloads to enhance immunogenicity. It is currently in the discovery or early preclinical stage of development for the treatment of solid tumors.
02
Targets
CD46 (CD46 Molecule)PVRL4 (Nectin cell adhesion molecule 4)SLAMF1 (Signaling lymphocytic activation molecule family member 1)SLAMF1 (SLAM family member 1)
Beyond the preview
Go deeper on CanVirex04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CanVirex04.